Private Foundation Funded
COG (Children's Oncology Group): U01CA180886 - 2017-present
Role: Institutional PI
PI: Hawkins
COG (Children's Oncology Group): U01CA180886: ANBL 2131 - 2023-present
Role: Study Co-chair
PI: Hawkins
CURE Childhood Cancer - 2015-2024
AflacST1501: Phase I Study of Abemaciclib (Cdk 4/6 inhibitor) in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Recurrent Solid Tumors Including Malignant Brain Tumors
Role: Co-Investigator
PI: Wetmore
Cannonball Kids’ cancer (CKc) Foundation
AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemotherapy in Children with Recurrent and/or Refractory Solid and CNS Tumors
Role: PI
Contracts
Celgene
AflacST1603: A Phase 1 Study Using Nab-paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Role: Co-PI
Institutional
Peach Bowl LegACy Fund -2020-2024
A Maintenance Protocol of Sirolimus in Combination with Metronomic Chemotherapy in Children with High-Risk Solid Tumors
Role: Co-PI
PI: Sutton
Peach Bowl LegACy Fund - 2022-2026
Pilot Study of Atezolizumab in Combination with Stereotactic Body Radiation Therapy (SBRT) and Surgery in Pediatric and AYA Patients with Pulmonary Recurrence of Osteosarcoma
Role: PI
Peach Bowl LegACy Fund - 2023-2026
A Phase 1b Study of Tegavivint, a TBL1 inhibitor, with Gemcitabine in Children, Adolescents, and Young Adults with Relapsed or Refractory Osteosarcoma
Role: PI